NervGen Pharma to Present at the Virtual Life Science Investor Forum
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company focused on neurorestorative therapeutics, has announced its upcoming presentation at the Virtual Life Sciences Investor Forum.
The company's President & CEO, Mike Kelly, will present on Thursday, March 13, 2025, at 12:00 p.m. EDT. The management team will be available for one-on-one virtual investor meetings during March 13-14 and March 17-18, 2025.
Individual and institutional investors, advisors, and analysts can pre-register for this interactive online event at VirtualInvestorConferences.com. For those unable to attend live, an archived webcast will be available on NervGen's website after the event.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), un'azienda biotech in fase clinica focalizzata su terapie neurorestorative, ha annunciato la sua prossima presentazione al Virtual Life Sciences Investor Forum.
Il Presidente e CEO dell'azienda, Mike Kelly, presenterà giovedì 13 marzo 2025, alle 12:00 EDT. Il team di gestione sarà disponibile per incontri virtuali individuali con gli investitori durante il 13-14 e il 17-18 marzo 2025.
Investitori individuali e istituzionali, consulenti e analisti possono registrarsi in anticipo per questo evento online interattivo su VirtualInvestorConferences.com. Per coloro che non possono partecipare dal vivo, una registrazione dell'evento sarà disponibile sul sito web di NervGen dopo l'evento.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), una empresa biotecnológica en etapa clínica centrada en terapias neurorestaurativas, ha anunciado su próxima presentación en el Virtual Life Sciences Investor Forum.
El presidente y CEO de la empresa, Mike Kelly, presentará el jueves 13 de marzo de 2025, a las 12:00 p.m. EDT. El equipo de gestión estará disponible para reuniones virtuales uno a uno con inversores durante el 13-14 y el 17-18 de marzo de 2025.
Inversores individuales e institucionales, asesores y analistas pueden preinscribirse para este evento en línea interactivo en VirtualInvestorConferences.com. Para aquellos que no puedan asistir en vivo, se dispondrá de una grabación del evento en el sitio web de NervGen después del evento.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF)는 신경 재생 치료제에 중점을 둔 임상 단계의 생명공학 회사로, Virtual Life Sciences Investor Forum에서의 발표를 발표했습니다.
회사의 사장 겸 CEO인 Mike Kelly는 2025년 3월 13일 목요일 오후 12시 EDT에 발표할 예정입니다. 경영진 팀은 2025년 3월 13-14일 및 17-18일 동안 투자자와의 일대일 가상 미팅을 위해 대기할 것입니다.
개인 및 기관 투자자, 자문가 및 분석가는 VirtualInvestorConferences.com에서 이 인터랙티브 온라인 이벤트에 사전 등록할 수 있습니다. 실시간 참석이 불가능한 분들을 위해, 이벤트 후 NervGen 웹사이트에서 아카이브된 웹캐스트가 제공될 예정입니다.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), une entreprise biopharmaceutique en phase clinique axée sur les thérapies neurorestauratives, a annoncé sa prochaine présentation lors du Virtual Life Sciences Investor Forum.
Le président et PDG de l'entreprise, Mike Kelly, présentera le jeudi 13 mars 2025, à 12h00 EDT. L'équipe de direction sera disponible pour des réunions virtuelles individuelles avec des investisseurs durant les 13-14 et 17-18 mars 2025.
Les investisseurs individuels et institutionnels, les conseillers et les analystes peuvent s'inscrire à l'avance pour cet événement en ligne interactif sur VirtualInvestorConferences.com. Pour ceux qui ne peuvent pas assister en direct, un enregistrement de l'événement sera disponible sur le site Web de NervGen après l'événement.
NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), ein biopharmazeutisches Unternehmen in der klinischen Phase, das sich auf neurorestaurative Therapeutika konzentriert, hat seine bevorstehende Präsentation beim Virtual Life Sciences Investor Forum angekündigt.
Der Präsident und CEO des Unternehmens, Mike Kelly, wird am Donnerstag, den 13. März 2025, um 12:00 Uhr EDT präsentieren. Das Managementteam steht während des 13.-14. und 17.-18. März 2025 für persönliche virtuelle Investorenmeetings zur Verfügung.
Einzel- und institutionelle Investoren, Berater und Analysten können sich im Voraus für dieses interaktive Online-Event unter VirtualInvestorConferences.com registrieren. Für diejenigen, die nicht live teilnehmen können, wird nach der Veranstaltung ein archivierter Webcast auf der Website von NervGen verfügbar sein.
- None.
- None.
Vancouver, British Columbia--(Newsfile Corp. - March 5, 2025) - NervGen Pharma Corp. (TSXV: NGEN) (OTCQB: NGENF), a clinical-stage biotech company dedicated to developing neurorestorative therapeutics, today announced that Mr. Mike Kelly, President & CEO, will be presenting at the Virtual Life Sciences Investor Forum hosted by OTC Markets Group and VirtualInvestorConferences.com, on Thursday, March 13, 2025, at 12:00 p.m. EDT. Members of management will be available for virtual one-on-one investor meetings on March 13-14 and March 17-18, 2025.
Individual and institutional investors, as well as advisors and analysts, are invited to pre-register and attend online at VirtualInvestorConferences.com for this live, interactive online event. If attendees are not able to join the event live on the day of the conference, an archived webcast will also be made available after the event on our website.
About NervGen
NervGen (TSXV: NGEN) (OTCQB: NGENF) is a clinical-stage biotech company dedicated to developing innovative treatments to promote nervous system repair in settings of neurotrauma and neurologic disease. The company is testing the clinical efficacy of its lead molecule, NVG-291, in a Phase 1b/2a clinical trial in spinal cord injury and has initiated preclinical evaluation of a new development candidate, NVG-300, in models of ischemic stroke, amyotrophic lateral sclerosis (ALS) and spinal cord injury. For more information, visit www.nervgen.com and follow NervGen on X, LinkedIn, and Facebook for the latest news on the company.
About NVG-291
NervGen holds exclusive worldwide rights to NVG-291, a first-in-class therapeutic peptide targeting nervous system repair. NVG-291's technology was licensed from Case Western Reserve University and is based on academic studies demonstrating the preclinical efficacy of NVG-291-R, the rodent prototype of NVG-291, in animal models of spinal cord injury. Effects of NVG-291-R reported in multiple independent academic studies include the promotion of neuroplasticity, remyelination, anti-inflammatory polarization of microglia, and functional improvement in preclinical models of spinal cord injury, stroke, and peripheral nervous system injury. NVG-291 has received Fast Track designation in spinal cord injury from the U.S. Food and Drug Administration.
Contacts
Huitt Tracey, Investor Relations
htracey@nervgen.com
604.537.2094
Bill Adams, Chief Financial Officer
info@nervgen.com
778.731.1711
David Schull or Ignacio Guerrero-Ros, Ph.D.
Russo Partners
david.schull@russopartnersllc.com
ignacio.guerrero-ros@russopartnersllc.com
858.717.2310
646.942.5604
Neither the TSX Venture Exchange nor its Regulation Services Provider (as that term is defined in the policies of the TSX Venture Exchange) accepts responsibility for the adequacy or accuracy of this release.
Cautionary Note Regarding Forward-Looking Statements
This news release may contain "forward-looking information" and "forward-looking statements" within the meaning of applicable Canadian and United States securities legislation (collectively, "forward-looking statements"). Such forward-looking statements herein include but are not limited to, the Company's current and future plans, expectations and intentions, results, levels of activity, performance, goals or achievements, or any other future events or developments constitute forward-looking statements, and the words "may", "will", "would", "should", "could", "expect", "plan", "intend", "trend", "indication", "anticipate", "believe", "estimate", "predict", "likely" or "potential", or the negative or other variations of these words or other comparable words or phrases, are intended to identify forward-looking statements. Forward-looking statements include, without limitation, statements relating to: the subject matter to be presented at the upcoming investor conference; the objectives, planned clinical endpoints, timing, expected rate of enrollment, and timing of data readout and study design of our Phase 1b/2a clinical trial of NVG-291 in individuals with spinal cord injury; the development plans, timelines, expected benefits, and prospective target indications for NVG-300; and the creation of neurorestorative therapeutics to promote nervous system repair in settings of neurotrauma and neurologic disease.
Forward-looking statements are based on estimates and assumptions made by the company in light of management's experience and perception of historical trends, current conditions and expected future developments, as well as other factors that we believe are appropriate and reasonable in the circumstances. In making forward-looking statements, we have relied on various assumptions, including, but not limited to: our ability to obtain future funding on favourable terms or at all; the accuracy of our financial projections; obtaining positive results in our clinical and other trials; our ability to obtain necessary regulatory approvals; our ability to arrange for the manufacturing of our product candidates and technologies; and general business, market and economic conditions.
Many factors could cause our actual results, level of activity, performance or achievements or future events or developments to differ materially from those expressed or implied by the forward-looking statements, including without limitation, a lack of revenue, insufficient funding, reliance upon key personnel, the uncertainty of the clinical development process, competition, and other factors set forth in the "Risk Factors" section of the company's most recently filed prospectus supplement, short form base shelf prospectus, annual information form, financial statements and management discussion and analysis all of which can be found on NervGen's profile on SEDAR+ at www.sedarplus.ca. All clinical development plans are subject to additional funding.
Readers should not place undue reliance on forward-looking statements made in this news release. Furthermore, unless otherwise stated, the forward-looking statements contained in this news release are made as of the date of this news release, and we have no intention and undertake no obligation to update or revise any forward-looking statements, whether as a result of new information, future events or otherwise, except as required by applicable law. The forward-looking statements contained in this news release are expressly qualified by this cautionary statement.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/243349